(Q35059001)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

review article

1 reference

title

Relationships among morphine metabolism, pain and side effects during long-term treatment: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference

Lona Louring Christrup

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

author name string

Gertrud Andersen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Per Sjøgren

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pain and Symptom Management

17 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

page(s)

74-91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

Morphine metabolism in man

17 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Pharmacokinetic Modeling of M6G Formation after Oral Administration of Morphine in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Characteristics of the gastrointestinal absorption of morphine in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine kinetics in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The Metabolism of Morphine and Heroin in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Forensic drug testing for opiates. II. Metabolism and excretion rate of morphine in humans after morphine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Glucuronidation in humans. Pharmacogenetic and developmental aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Glucuronidation of morphine in human kidney microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Presystemic glucuronidation of morphine in humans and rhesus monkeys: subcellular distribution of the UDP-glucuronyltransferase in the liver and intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Human brain metabolism of morphine and naloxone

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Hepatic extraction of morphine is impaired in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Extrahepatic metabolism of morphine occurs in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The pharmacokinetics of morphine and morphine glucuronides in kidney failure

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The metabolism and bioavailability of morphine in patients with severe liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Influence of renal function on the elimination of morphine and morphine glucuronides.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Kinetics of morphine in patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive‐care patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Oral morphine in cancer pain: influences on morphine and metabolite concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-6-glucuronide disposition in renal impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine intoxication in renal failure: the role of morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Long lasting respiratory depression induced by morphine-6-glucuronide?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Ethnic differences in response to morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Antidepressants increase bioavailability of morphine in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine metabolism in children

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Age and morphine analgesia in cancer patients with postoperative pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Differences in epidural morphine requirements between elderly and young patients after abdominal surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Age-related morphine kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Studies on morphine disposition: plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers*

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Disposition of morphine-6-glucuronide and morphine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Steady-State Kinetics and Dynamics of Morphine in Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-6-glucuronide, a potent mu agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Lack of Analgesic Activity of Morphine-6-glucuronide after Short-term Intravenous Administration in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The analgesic activity of morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Analgesic responses to intrathecal morphine in relation to CSF concentrations of morphine-3,beta-glucuronide and morphine-6,beta-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or morphine-3-glucuronide in the awake dog

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Chronic nausea and morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-3-glucuronide--a potent antagonist of morphine analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Morphine-3-glucuronide: silent regulator of morphine actions.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

1 reference

7 January 2021

Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Opiate-induced seizures: a study of mu and delta specific mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Intrathecal high dose morphine produces hyperalgesia in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Inhibition of clonic seizure-like excitatory effects induced by intrathecal morphine using two NMDA receptor antagonists: MK-801 and ACEA-1011.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

1 reference

7 January 2021

Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Epidural and intravenous opioid-induced neuroexcitation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Epileptic seizure associated with intracerebroventricular and intrathecal morphine bolus

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900531-6

7 January 2021

10.1016/S0885-3924(02)00531-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565191%20AND%20SRC:MED&resulttype=core&format=json

release_pfw36yzghjggrn35xnpgoqnhka

17 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pfw36yzghjggrn35xnpgoqnhka

24 November 2022

mapped directly with Wikidata item

1 reference